Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer
Authors
Keywords
-
Journal
ANNALS OF MEDICINE
Volume 47, Issue 5, Pages 359-369
Publisher
Informa UK Limited
Online
2015-07-09
DOI
10.3109/07853890.2015.1043140
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Host effects contributing to cancer therapy resistance
- (2015) Ofrat Beyar Katz et al. DRUG RESISTANCE UPDATES
- Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
- (2015) Steven J Edwards et al. HEALTH TECHNOLOGY ASSESSMENT
- Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients
- (2015) Marina Bagnoli et al. Oncotarget
- Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance
- (2015) Eran E. Bram et al. NEOPLASIA
- Epigenetics of cancer stem cells: Pathways and therapeutics
- (2014) Samriddhi Shukla et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
- (2014) R M Glasspool et al. BRITISH JOURNAL OF CANCER
- Epigenetic Targeting of Ovarian Cancer Stem Cells
- (2014) Yinu Wang et al. CANCER RESEARCH
- “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
- (2014) Alison Davis et al. GYNECOLOGIC ONCOLOGY
- The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer
- (2014) John K. Chan et al. GYNECOLOGIC ONCOLOGY
- miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6
- (2014) Xiaolan Zhu et al. INTERNATIONAL JOURNAL OF CANCER
- Deregulation of miR-128 in Ovarian Cancer Promotes Cisplatin Resistance
- (2014) Bing Li et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention
- (2014) Brendan Ffrench et al. Molecular Cancer
- Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
- (2014) Hariharan Easwaran et al. MOLECULAR CELL
- Regulation of microRNA biogenesis
- (2014) Minju Ha et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- MicroRNA 130b enhances drug resistance in human ovarian cancer cells
- (2014) Can Zong et al. TUMOR BIOLOGY
- Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
- (2014) Deborah J. Marsh et al. Frontiers in Oncology
- Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly
- (2013) X. Zhang et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients
- (2013) J. M. Flanagan et al. ANNALS OF ONCOLOGY
- MiR-200c and HuR in ovarian cancer
- (2013) Silvia Prislei et al. BMC CANCER
- MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples
- (2013) Xiao Li et al. BMC CANCER
- Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer
- (2013) J H Huh et al. BRITISH JOURNAL OF CANCER
- Review of processing and analysis methods for DNA methylation array data
- (2013) C S Wilhelm-Benartzi et al. BRITISH JOURNAL OF CANCER
- Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis
- (2013) Elena Lum et al. GYNECOLOGIC ONCOLOGY
- Downregulation ofmiR-29contributes to cisplatin resistance of ovarian cancer cells
- (2013) Pei-Ning Yu et al. INTERNATIONAL JOURNAL OF CANCER
- MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells
- (2013) Yu-mei Rao et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine
- (2013) Y Xiang et al. ONCOGENE
- Transcriptional Suppression, DNA Methylation, and Histone Deacetylation of the Regulator of G-Protein Signaling 10 (RGS10) Gene in Ovarian Cancer Cells
- (2013) Mourad W. Ali et al. PLoS One
- A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
- (2013) A. Vecchione et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin
- (2013) J Cai et al. Oncogenesis
- The cyclin-dependent kinase inhibitor p57Kip2 is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
- (2012) H M Coley et al. BRITISH JOURNAL OF CANCER
- Epigenetic Resensitization to Platinum in Ovarian Cancer
- (2012) D. Matei et al. CANCER RESEARCH
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- Basic concepts of epigenetics
- (2012) Elizabeth A. Mazzio et al. Epigenetics
- MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells
- (2012) Weiwei Cheng et al. FEBS Journal
- Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells
- (2012) Xin Fu et al. FEBS LETTERS
- A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
- (2012) Don S. Dizon et al. GYNECOLOGIC ONCOLOGY
- Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer
- (2012) Don S. Dizon et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer
- (2012) Ning Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel
- (2012) D. M. Cittelly et al. MOLECULAR CANCER THERAPEUTICS
- Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility
- (2012) D. Ziliak et al. MOLECULAR CANCER THERAPEUTICS
- Functions of DNA methylation: islands, start sites, gene bodies and beyond
- (2012) Peter A. Jones NATURE REVIEWS GENETICS
- Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells
- (2012) N Chapman-Rothe et al. ONCOGENE
- miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
- (2012) M T M van Jaarsveld et al. ONCOGENE
- Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
- (2012) C Zeller et al. ONCOGENE
- A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies
- (2011) Julie Bauman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer
- (2011) N. Syed et al. CANCER RESEARCH
- Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival
- (2011) W. Dai et al. CLINICAL CANCER RESEARCH
- CpG islands and the regulation of transcription
- (2011) A. M. Deaton et al. GENES & DEVELOPMENT
- Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1
- (2011) Chun Yang et al. GYNECOLOGIC ONCOLOGY
- Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1
- (2011) Benjamin Boyerinas et al. INTERNATIONAL JOURNAL OF CANCER
- MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance
- (2011) G. Ye et al. JOURNAL OF CELL SCIENCE
- miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1
- (2011) Fanfei Kong et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2
- (2011) S. Rizzo et al. MOLECULAR CANCER THERAPEUTICS
- miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response
- (2011) Bogdan Mateescu et al. NATURE MEDICINE
- Epigenome-wide association studies for common human diseases
- (2011) Vardhman K. Rakyan et al. NATURE REVIEWS GENETICS
- Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell
- (2011) Wei Yu et al. PLoS One
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
- (2010) Siqing Fu et al. CANCER
- A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer
- (2010) Fang Fang et al. CANCER
- Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo
- (2010) Sha Hu et al. CANCER BIOLOGY & THERAPY
- Structure and Function of Mammalian DNA Methyltransferases
- (2010) Renata Zofia Jurkowska et al. CHEMBIOCHEM
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
- (2010) Helen J. Mackay et al. EUROPEAN JOURNAL OF CANCER
- Dynamic changes in the human methylome during differentiation
- (2010) L. Laurent et al. GENOME RESEARCH
- MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells
- (2010) Zhimin Li et al. GYNECOLOGIC ONCOLOGY
- Replication timing-related and gene body-specific methylation of active human genes
- (2010) Dvir Aran et al. HUMAN MOLECULAR GENETICS
- HERV-K Hypomethylation in Ovarian Clear Cell Carcinoma Is Associated With a Poor Prognosis and Platinum Resistance
- (2010) Kanokwan Iramaneerat et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Quantitative detection of DNA methylation states in minute amounts of DNA from body fluids
- (2010) Anupam Paliwal et al. METHODS
- Conserved role of intragenic DNA methylation in regulating alternative promoters
- (2010) Alika K. Maunakea et al. NATURE
- Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer
- (2010) Constanze Zeller et al. Therapeutic Advances in Medical Oncology
- Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer
- (2009) Meng Li et al. BMC Medical Genomics
- Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo
- (2009) N Steele et al. BRITISH JOURNAL OF CANCER
- Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC)
- (2009) Parvesh Chaudhry et al. CANCER INVESTIGATION
- DNA methylation and methyl-CpG binding proteins: developmental requirements and function
- (2009) Ozren Bogdanović et al. CHROMOSOMA
- The promises and pitfalls of epigenetic therapies in solid tumours
- (2009) Janet S. Graham et al. EUROPEAN JOURNAL OF CANCER
- Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients
- (2009) Ram Eitan et al. GYNECOLOGIC ONCOLOGY
- Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer
- (2009) Linda J. Nicholson et al. INTERNATIONAL JOURNAL OF CANCER
- Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway
- (2009) Her-Young Su et al. INTERNATIONAL JOURNAL OF CANCER
- Rethinking how DNA methylation patterns are maintained
- (2009) Peter A. Jones et al. NATURE REVIEWS GENETICS
- MicroRNA Microarray Identifies Let-7i as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer
- (2008) N. Yang et al. CANCER RESEARCH
- MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN
- (2008) H. Yang et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now